An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK

PharmacoEconomics

Volumn 22, Issue 8, 2004, Pages 525-535

  Scuffham, Paul A ^a,b   Chaplin, Stephen ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATIN;

ACUTE HEART INFARCTION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; EVALUATION; HEALTH CARE COST; HEART DEATH; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PATIENT COUNSELING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; SIMULATION; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FATTY ACIDS, MONOUNSATURATED; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; MARKOV CHAINS; MODELS, ECONOMIC; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 3042778734     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422080-00004     Document Type: Article

References (29)

1. National Institute for Clinical Excellence. Final appraisal determination: coronary artery stents. London: National Institute for Clinical Excellence, 2003
2. Department of Health. NHS reference costs 2002 Department of Health, London, 2002 [online]. Available from URL: http://www.doh.gov.uk/nhsexec/ REFCOSTS/refcosts2002.pdf [Accessed 2003 Sep 18]
3. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360 (9326): 7-22
4. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287 (24): 3215-22
5. Data Pro. Williamstown (MA): TreeAge Software Inc, 2002
6. Cleland JG, Walker A. Is medical treatment for angina the most cost-effective option? Eur Heart J 1997; 18 Suppl. B: B35-42
7. Cleland JG, Walker A. Therapeutic options and cost considerations in the treatment of ischemic heart disease. Cardiovasc Drugs Ther 1998; 12 Suppl. 3: 225-32
8. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312 (7044): 1443-8
9. Troche CJ, Tacke J, Hinzpeter B, et al. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 1998; 19 Suppl. C: C59-65
10. DeWilde S, Carey IM, Bremner SA, et al. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89 (4): 417-21
11. Briggs A. Handling uncertainty in economic evaluations and presenting the results. In: Drummond MF, McGuire A, editors. Economic evaluation in health care. Oxford: Oxford University Press, 2001: 172-214
12. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38
13. Melsop KA, Boothroyd DB, Hlatky MA. Quality of life and time trade-off utility measures in patients with coronary artery disease. Am Heart J 2003; 145 (1): 36-41
14. National Institute for Clinical Excellence. Health technology appraisal: review of coronary artery stents and appraisal of drug eluting stents. London: National Institute for Clinical Excellence, 2003
15. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 2001; 344 (15): 1117-24
16. Greiner W, Weijen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states: results from a six-country study. Eur J Health Econ 2003; 4 (3): 222-31
17. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 45 Clinical and Biomedical Computing Ltd, 2001 [online]. Available from URL: www.bnf.org.uk [Accessed 2002 Apr 22]
18. Department of Health. Prescription cost analysis 2001 Department of Health, London, 2002 [online]. Available from URL: http://www.doh.gov.uk/stats/ pca2001.htm [Accessed 2003 Mar 18]
19. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001 Personal Social Services Research Unit, University of Kent, Canterbury, 2002 [online]. Available from URL: http://www.ukc.ac.uk/PSSRU [Accessed 2003 May 30]
20. Norris RM, Wong PS, Dixon G, et al. Fatality outside hospital from acute coronary events in three British health districts, 1994-5. BMJ 1998; 316 (7137): 1065-70
21. National Institute for Clinical Excellence. Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal. London: National Institute for Clinical Excellence, 2001
22. Zethraeus N, Johannesson M, Jönsson B, et al. Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies. Pharmacoeconomics 2003; 21 (1): 39-48
23. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
24. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis or primary prevention with pravastatin. BMJ 1997; 315: 1577-82
25. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82: 1357-63
26. Prosser LA, Stinnett AA, Glodman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000; 132 (10): 769-79
27. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors: whom to treat? Eur Heart J 2001; 22: 751-61
28. Department of Health. Hospital episode statistics 2001-2002 Department of Health, London, 2002 [online]. Available from URL: http://www.doh.gov.uk/hes/ tables/tbcv101e.xls [Accessed 2003 Sep 18]
29. Department of Health. Hospital episode statistics 2000-2001 Department of Health, London, 2001 [online]. Available from URL: http://www.doh.gov.uk/hes/ tables/tbcv100e.xls [Accessed 2003 Sep 18]